Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).

Molnár I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Chen TC, Holick MF, Cambra S, McQuellon RP, Schwartz GG.

Leukemia. 2007 May;21(5):1089-92. Epub 2007 Mar 8. No abstract available.

PMID:
17344922
2.

Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly.

Tellioglu A, Basaran S, Guzel R, Seydaoglu G.

Maturitas. 2012 Aug;72(4):332-8. doi: 10.1016/j.maturitas.2012.04.011. Epub 2012 May 20.

PMID:
22613271
3.

Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting.

Hackman KL, Gagnon C, Briscoe RK, Lam S, Anpalahan M, Ebeling PR.

Med J Aust. 2010 Jun 21;192(12):686-9.

PMID:
20565345
4.

The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency.

Leventis P, Kiely PD.

Scand J Rheumatol. 2009 Mar-Apr;38(2):149-53. doi: 10.1080/03009740802419081.

PMID:
18991184
5.

Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine.

Spitzer TR, Lazarus HM, Crum ED, Weisman R.

Med Pediatr Oncol. 1988;16(1):17-20.

PMID:
3340062
6.

Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease.

Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW.

J Nephrol. 2009 Jan-Feb;22(1):75-82.

PMID:
19229821
7.

[Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 [1 alpha(OH)D3]].

Irino S, Taoka T.

Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1183-90. Japanese.

PMID:
2837981
8.

High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency.

von Restorff C, Bischoff-Ferrari HA, Theiler R.

Bone. 2009 Oct;45(4):747-9. doi: 10.1016/j.bone.2009.06.012. Epub 2009 Jun 17.

PMID:
19539796
9.

Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.

Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, Rosati P, Venturino C, Varaldo R, Gobbi M, Ghio R, Rodriguez G.

Eur J Haematol. 2004 Feb;72(2):113-20.

PMID:
14962248
10.

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.

Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B, Jorde R.

Osteoporos Int. 2012 Jan;23(1):201-11. doi: 10.1007/s00198-011-1752-5. Epub 2011 Sep 10.

PMID:
21909730
11.
12.

[Vitamin D supplementation in institutionalized elderly. Effects of vitamin D3 (100,000 IU) orally administered every 3 months on serum levels of 25-hydroxyvitamin D].

Zeghoud F, Jardel A, Garabedian M, Salvatore R, Moulias R.

Rev Rhum Mal Osteoartic. 1990 Nov;57(11):809-13. French.

PMID:
1963239
13.
14.

The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit.

Premaor MO, Scalco R, da Silva MJ, Froehlich PE, Furlanetto TW.

J Bone Miner Metab. 2008;26(6):603-8. doi: 10.1007/s00774-008-0858-0. Epub 2008 Nov 1.

PMID:
18979160
15.

The effect of a single oral megadose of vitamin D provided as either ergocalciferol (D₂) or cholecalciferol (D₃) in alcoholic liver cirrhosis.

Malham M, Peter Jørgensen S, Lauridsen AL, Ott P, Glerup H, Dahlerup JF.

Eur J Gastroenterol Hepatol. 2012 Feb;24(2):172-8. doi: 10.1097/MEG.0b013e32834d1755.

PMID:
22027703
17.

The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function.

Pekkarinen T, Välimäki VV, Aarum S, Turpeinen U, Hämäläinen E, Löyttyniemi E, Välimäki MJ.

Clin Endocrinol (Oxf). 2010 Apr;72(4):455-61. doi: 10.1111/j.1365-2265.2009.03637.x. Epub 2009 May 25.

PMID:
19486025
18.

Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome.

Koeffler HP, Aslanian N, O'Kelly J.

Leuk Res. 2005 Nov;29(11):1259-62. Epub 2005 Apr 26.

PMID:
16164982
19.

Treatment of MDS with special reference to the effects of androgen on ineffective erythropoiesis.

Mitsutani S.

Nihon Ketsueki Gakkai Zasshi. 1988 Dec;51(8):1455-60. No abstract available.

PMID:
2854695
20.

High-dose oral vitamin D3 supplementation in the elderly.

Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR.

Osteoporos Int. 2009 Aug;20(8):1407-15. doi: 10.1007/s00198-008-0814-9. Epub 2008 Dec 20.

PMID:
19101755

Supplemental Content

Support Center